Approach

Summary

Licensing status

Publication and contact information

Drug platforms

Antigen-specific T cells generated from induced pluripotent stem (iPS) cells derived for adoptive immunotherapy

Two separate groups showed that iPS cells derived from mature CD8+ T cells can be differentiated into antigen-specific T cells that may be useful for overcoming T cell exhaustion during adoptive immunotherapy. Mature CD8+ T cells were reprogrammed into iPS cells and then differentiated into T cells with the same functionality and antigen specificity as the original CD8+ T cells. One group used mature CD8+ T cells from an HIV-infected patient to generate
T cells that showed antigen-specific activity against HIV p27 (nef). The other group used CD8+ T cells from a patient with melanoma to generate T cells that showed antigen-specific activity against melan-A (MLANA; MART1). Next steps for both groups include testing the regenerated human T cells in animal models.

SciBX 6(4); doi:10.1038/scibx.2013.100
Published online Jan. 31, 2013

Patent application filed for findings in first study; available for licensing from Megakaryon Corp.

Contact: Genjiro Miwa, Mgakaryon Corp., Tokyo, Japan

phone: 81-3-3536-6000

e-mail:
gmiwa@megakaryon.com


Findings in second study unpatented; licensing status not applicable

Nishimura, T. et al. Cell Stem Cell; published online Jan. 3, 2013;
doi:10.1016/j.stem.2012.11.002
Contact: Hiromitsu Nakauchi, The University of Tokyo, Tokyo, Japan
e-mail:
nakauchi@ims.u-tokyo.ac.jp


Vizcardo, R. et al. Cell Stem Cell; published online Jan. 3, 2013;
doi:10.1016/j.stem.2012.12.006
Contact: Hiroshi Kawamoto, RIKEN Research Center for Allergy and Immunology, Yokohama, Japan
e-mail:
kawamoto@rcai.riken.jp